Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 09, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary Shares by six individuals on January 05, 2006, through the Company's ShareReward Plan. The shares were purchased at a price of GBP15.01 per Ordinary Share under the Dividend Reinvestment element of the Plan. The specific acquisitions were:
- Mr J S Heslop: 7 Ordinary Shares
- Mr R Bondy: 7 Ordinary Shares
- Dr D Pulman: 4 Ordinary Shares
- Mr C Viehbacher: 2 Ordinary Shares
- Mrs J V Younger: 7 Ordinary Shares
- Mr A P Witty: 7 Ordinary Shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) regarding the notification of these specific transactions.
Investor Verification Points
- Verify the share price of GBP15.01 per Ordinary Share on January 05, 2006.
- Confirm the total number of shares acquired by the listed directors under the Dividend Reinvestment element.
- Review the terms of the ShareReward Plan entered into on October 05, 2001.